Tamtam Try Tamtam free
Evonik logo

Evonik account plan

Tailor-made chemical industry solutions

At a glance

Evonik is an Essen-based specialty chemicals group with FY2025 sales of €14,069 million, 31,053 employees and production at 98 locations in 27 countries.

Evonik is a global specialty chemicals company headquartered in Essen, Germany, selling intermediates such as silicas, amino acids, polymers, additives and pharmaceutical ingredients mostly to industrial customers; no end-market accounts for more than 20% of sales. It produces at 98 locations in 27 countries and makes 82% of sales outside Germany. FY2025 sales were €14,069 million (-7%), adjusted EBITDA €1,874 million and net income €265 million, with 31,053 employees at year-end. RAG-Stiftung is the majority shareholder. Since early September 2026 Dr. Claus Rettig has led the company as interim CEO while CEO Christian Kullmann is ill.

Business units

Strategic priorities

ROCE of around 11%
From 2026 ROCE is the central management metric, targeted at around 11% mid-term against 6.1% in 2025, with cash conversion above 40% and a solid investment grade rating.
Evonik Tailor Made cost programme
Around €400 million of annual savings and 2,000 fewer jobs by end-2026, extended in June 2026 with around 3,200 more job cuts planned for 2027-2029.
Portfolio restructuring
A new owner is sought for Oxeno, and SYNEQT is open to investors taking stakes or even a complete sale.
Innovation-led growth
Next Generation Solutions reached 48% of sales with a target of over 50% by 2030, and three innovation growth areas should add €1.5 billion of sales by 2032.
Regional balance
An aim of one-third of sales in each of Europe, the Americas and Asia, against EMEA 48%, Americas 29% and Asia-Pacific 23% in 2025.
Independence and selective consolidation
Evonik rejected BASF's offer of €24 per share in November 2026 and says it wants to take part in consolidating the chemical industry from its own position.

Latest results

In Q3 2026 sales rose 13% to €3,825 million and adjusted EBITDA 40% to €629 million (margin 16.4%), driven by Advanced Technologies after the war in the Middle East disrupted Asian competitors' supply. Over the nine months sales were €11,144 million (+4%), adjusted EBITDA €1,734 million (+14%) and free cash flow €601 million, while €313 million of structural expenses were booked for the second phase of Evonik Tailor Made. Guidance was raised at mid-year and then narrowed to the upper half of €2.0-2.2 billion adjusted EBITDA for 2026, with ROCE considerably above 2025 and capex around €750 million. Evonik expects the Middle East effects to keep fading and methionine prices to ease to year-end.

Investments and deals

Capacity in growth businesses
An alkoxides plant in Singapore, the first fumed aluminum oxide plant in Asia (Yokkaichi, Japan) for battery separators, SEPURAN membrane capacity in Austria and precipitated silica in Charleston (USA).
US backward integration and pharma lipids
A methylmercaptan plant in Mobile (USA) completing methionine backward integration in 2026, and a pharmaceutical lipids plant in Lafayette (USA) with over US$100 million of US support.
Capex discipline
Capex cash outflows were €748 million in 2025 and are guided around €750 million for 2026; every project must earn at least the cost of capital.
Innovation and venture
R&D spend of €418 million in 2025, a new Evonik Innovation Factory, and Evonik Venture Capital with a €150 million Sustainability Tech Fund.

Challenges and risks

Weak returns
ROCE fell to 6.1% in 2025 against a 10.0% cost of capital, and 2025 guidance was cut twice after demand fell from Q2.
Chinese capacity and US tariffs
New capacity and aggressive pricing from China and US trade policy weigh on prices; the CEO blamed an erratic U.S. tariff policy for the 2025 downswing.
Fading one-off demand
2026 gains came partly from customer stockpiling after the Middle East war and the Strait of Hormuz closure, effects that are fading.
Oxeno and impairments
Oxeno took a €119 million impairment in H1 2026, and Q3 brought €264 million of impairments in Care and Organics.
Cyber and macro risks
Cyberattacks, a fall in C4 chemical prices and volumes and a macroeconomic downturn are the material individual risks.

What leadership says

“The combination of an erratic U.S. tariff policy and the resulting uncertainty among our customers wrong-footed us.”

Christian Kullmann, Chairman of the Executive Board · Statement at the Annual Shareholders' Meeting, June 3, 2026.

“We intend to find a new owner for Oxeno, our C4 chemicals business.”

Christian Kullmann, Chairman of the Executive Board · Statement at the Annual Shareholders' Meeting, June 3, 2026.

“We hold our future in our own hands.”

Christian Kullmann, Chairman of the Executive Board · Statement at the Annual Shareholders' Meeting, June 3, 2026.

Where a supplier can help

Administrative efficiency
Evonik Tailor Made (priority) targets leaner administration with flatter hierarchies, a fit for automation, shared-services and process software providers.
Carve-out and divestment support
Selling Oxeno and opening SYNEQT to investors (priority: portfolio restructuring) need M&A advisory, separation IT and transitional services.
Plant engineering for growth capacity
New plants in Singapore, Japan, Austria and the USA (investments) open opportunities for engineering, equipment and construction suppliers.
Cybersecurity
Cyberattacks, with ransomware the main threat, are a material risk (challenge), pointing to OT and IT security services.
Commercial growth in the Americas and Asia
The regional balance target (priority) favours partners in distribution, market intelligence and sales enablement outside Europe.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Evonik?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Evonik

What does Evonik do?

Evonik makes specialty chemicals such as silicas, amino acids for animal feed, high-performance polymers, additives and pharmaceutical ingredients, sold mostly to industrial customers worldwide.

What is Evonik's revenue?

FY2025 sales were €14,069 million with adjusted EBITDA of €1,874 million. Nine-month 2026 sales were €11,144 million.

How many employees does Evonik have?

31,053 at the end of 2025 and 30,356 at June 30, 2026, falling under the Evonik Tailor Made programme.

Who leads Evonik?

Christian Kullmann is Chairman of the Executive Board; Dr. Claus Rettig has been interim CEO since early September 2026 while Kullmann is ill. Michael Rauch is CFO since May 1, 2026.

Did Evonik accept BASF's takeover offer?

No. BASF most recently offered €24 per share, valuing Evonik at more than €11 billion; Evonik rejected it and says it remains independent.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)